Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Kashani-Sabet, S. Venna, M. Nosrati, J. Rangel, A. Sucker, F. Egberts, F. Baehner, J. Simko, S. Leong, C. Haqq, A. Hauschild, D. Schadendorf, James Miller, R. Sagebiel (2009)
A Multimarker Prognostic Assay for Primary Cutaneous MelanomaClinical Cancer Research, 15
L. Rodrigues, J. Teixeira, F. Schmitt, M. Paulsson, Helena Lindmark-Mänsson (2007)
The Role of Osteopontin in Tumor Progression and Metastasis in Breast CancerCancer Epidemiology Biomarkers & Prevention, 16
J. Smith (2011)
Serum 25-Hydroxyvitamin D3 Levels Are Associated With Breslow Thickness at Presentation and Survival From MelanomaYearbook of Dermatology and Dermatologic Surgery, 2011
Valerie Brown (2004)
Hazardous Waste: Electronics, Lead, and LandfillsEnvironmental Health Perspectives, 112
C. Balch, J. Gershenwald, S. Soong, J. Thompson, M. Atkins, D. Byrd, A. Buzaid, A. Cochran, D. Coit, Shouluan Ding, A. Eggermont, K. Flaherty, P. Gimotty, J. Kirkwood, K. McMasters, M. Mihm, D. Morton, M. Ross, A. Sober, V. Sondak (2009)
Final version of 2009 AJCC melanoma staging and classification.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 36
Hema Rangaswami, Anuradha Bulbule, G. Kundu (2006)
Osteopontin: role in cell signaling and cancer progression.Trends in cell biology, 16 2
S. Alonso, L. Tracey, P. Ortiz, R. Pajares, A. Sánchez-Aguilera, M. Artiga, M. Piris, J. Rodríguez-Peralto
Epithelial-mesenchymal Transition as a Major Determinant a High-throughput Study in Melanoma Identifies Updated Version Material Supplementary Cited Articles Citing Articles E-mail Alerts a High-throughput Study in Melanoma Identifies Epithelial- Mesenchymal Transition as a Major Determinant of Meta
J. Blasberg, H. Pass, Chandra Goparaju, R. Flores, Suzie Lee, J. Donington (2010)
Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 6
S. Isa, T. Kawaguchi, S. Teramukai, K. Minato, Y. Ohsaki, K. Shibata, T. Yonei, K. Hayashibara, M. Fukushima, M. Kawahara, K. Furuse, P. Mack (2009)
Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer: Results from JMTO LC 0004Journal of Thoracic Oncology, 4
A. Paschen, A. Sucker, B. Hill, Iris Moll, M. Zapatka, X. Nguyen, G. Sim, Isabelle Gutmann, J. Hassel, J. Becker, A. Steinle, D. Schadendorf, S. Ugurel (2009)
Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100BClinical Cancer Research, 15
The present study was funded by
H. Kluger, K. Hoyt, Antonella Bacchiocchi, T. Mayer, J. Kirsch, Y. Kluger, M. Sznol, S. Ariyan, A. Molinaro, R. Halaban (2011)
Plasma Markers for Identifying Patients with Metastatic MelanomaClinical Cancer Research, 17
K. Flaherty, I. Puzanov, Kevin Kim, A. Ribas, G. McArthur, J. Sosman, P. O'dwyer, Richard Lee, J. Grippo, K. Nolop, P. Chapman (2010)
Inhibition of mutated, activated BRAF in metastatic melanoma.The New England journal of medicine, 363 9
A. Bellahcène, V. Castronovo, K. Ogbureke, L. Fisher, N. Fedarko (2008)
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancerNature Reviews Cancer, 8
P. Wheatley-Price, Boming Yang, D. Patsios, D. Patel, Clement Ma, Wei Xu, N. Leighl, R. Feld, B.C. Cho, B. O’Sullivan, H. Roberts, Ming-Sound Tsao, M. Tammemagi, M. Anraku, Zhuo Chen, M. Perrot, Geoffrey Liu (2010)
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 20
C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbé, J. Baurain, A. Testori, J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. Miller, P. Gascón, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, Tai-Tsang Chen, R. Humphrey, A. Hoos, J. Wolchok (2011)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.The New England journal of medicine, 364 26
M. Hofmann, Felix Gussmann, A. Fritsche, S. Biesold, B. Schicke, I. Küchler, C. Voit, U. Trefzer (2009)
Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanomaMelanoma Research, 19
C. Conway, A. Mitra, Rosalyn Jewell, J. Randerson-Moor, Samira Lobo, Jrmie Nsengimana, Sara Edward, D. Sanders, M. Cook, B. Powell, A. Boon, F. Elliott, F. Kort, M. Knowles, D. Bishop, J. Newton-Bishop (2009)
Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free SurvivalClinical Cancer Research, 15
J. Rangel, M. Nosrati, S. Torabian, L. Shaikh, S. Leong, C. Haqq, James Miller, Richard Sagebiel, M. Kashani-Sabet (2008)
Osteopontin as a molecular prognostic marker for melanomaCancer, 112
J. Newton-Bishop, S. Beswick, J. Randerson-Moor, Yu-Mei Chang, P. Affleck, F. Elliott, M. Chan, Susan Leake, Birute Karpavicius, Sue Haynes, Kairen Kukalizch, L. Whitaker, S. Jackson, E. Gerry, C. Nolan, C. Bertram, J. Marsden, D. Elder, J. Barrett, D. Bishop (2009)
Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 32
Tobias Wind, Michael Messenger, D. Thompson, P. Selby, R. Banks (2011)
Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ionsAnnals of Clinical Biochemistry, 48
D. Denhardt (2005)
Osteopontin expression correlates with melanoma invasion.The Journal of investigative dermatology, 124 5
Gogas (2009)
Biomarkers in melanomaAnn Oncol, 20
T. Maier, R. Laubender, R. Sturm, A. Klingenstein, H. Korting, T. Ruzicka, C. Berking (2012)
Osteopontin expression in plasma of melanoma patients and in melanocytic tumoursJournal of the European Academy of Dermatology and Venereology, 26
A. Smith, K. Hoek, D. Becker (2005)
Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomasCancer Biology & Therapy, 4
Jochen Jaeger, D. Koczan, H. Thiesen, S. Ibrahim, G. Gross, R. Spang, M. Kunz (2007)
Gene Expression Signatures for Tumor Progression, Tumor Subtype, and Tumor Thickness in Laser-Microdissected Melanoma TissuesClinical Cancer Research, 13
V. Kulasingam, E. Diamandis (2008)
Strategies for discovering novel cancer biomarkers through utilization of emerging technologiesNature Clinical Practice Oncology, 5
Alonso (2007)
A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasisCancer Res, 67
Rittling (2004)
Role of osteopontin in tumour progressionBr J Cancer, 90
J. Soikkeli, P. Podlasz, M. Yin, P. Nummela, T. Jahkola, S. Virolainen, L. Krogerus, P. Heikkilä, K. Smitten, O. Saksela, E. Hölttä (2010)
Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth.The American journal of pathology, 177 1
R. Das, S. Philip, Ganapati Mahabeleshwar, Anuradha Bulbule, G. Kundu (2005)
Osteopontin: It's Role in Regulation of Cell Motility and Nuclear Factor κB‐mediated Urokinase Type Plasminogen Activator ExpressionIUBMB Life, 57
V. Barak, I. Kaiserman, S. Frenkel, Keren Hendler, I. Kalickman, J. Pe’er (2011)
The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1).Anticancer research, 31 1
C. Slingluff, R. Vollmer, D. Reintgen, H. Seigler (1988)
Lethal “Thin” Malignant Melanoma: Identifying Patients at RiskAnnals of Surgery, 208
Yong Li, Liang Li, J. Wang, X. Kan, Jianshu Lu (2012)
Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosisMedical Oncology, 29
Jian Sun, Hong-mei Xu, Hai-jun Zhou, Q. Dong, Yue Zhao, Li-yun Fu, Zhenyu Hei, Q. Ye, N. Ren, H. Jia, L. Qin (2009)
The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 136
Leisl Packer, S. Pavey, A. Parker, M. Stark, P. Johansson, B. Clarke, P. Pollock, M. Ringnér, N. Hayward (2006)
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.Carcinogenesis, 27 9
J. Homsi, M. Kashani-Sabet, J. Messina, A. Daud (2005)
Cutaneous melanoma: prognostic factors.Cancer control : journal of the Moffitt Cancer Center, 12 4
I. Reiniger, A. Wolf, U. Welge-Lüssen, A. Mueller, A. Kampik, U. Schaller (2007)
Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.American journal of ophthalmology, 143 4
(2007)
StataCorp: Stata Statistical Software: Release 10. College Station
S. Sim, Michael Messenger, W. Gregory, Tobias Wind, N. Vasudev, J. Cartledge, D. Thompson, P. Selby, R. Banks (2012)
Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinomaBritish Journal of Cancer, 107
H. Sennels, Søren Jacobsen, Tonny Jensen, M. Hansen, Mikkel Ǿstergaard, Hans Nielsen, Steen Sørensen (2007)
Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high‐sensitivity C‐reactive proteinScandinavian Journal of Clinical and Laboratory Investigation, 67
S. Kadkol, A. Lin, V. Barak, I. Kalickman, L. Leach, K. Valyi‐Nagy, D. Majumdar, S. Setty, A. Maniotis, R. Folberg, J. Pe’er (2006)
Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.Investigative ophthalmology & visual science, 47 3
Ingrid Haritoglou, A. Wolf, T. Maier, C. Haritoglou, R. Hein, U. Schaller (2009)
Osteopontin and ‘Melanoma Inhibitory Activity’: Comparison of Two Serological Tumor Markers in Metastatic Uveal Melanoma PatientsOphthalmologica, 223
(2007)
Serologic and immunohistochemical prognostic biomarkers of cutaneous malignanciesArch Dermatol Res, 298
An effective circulating tumour marker is needed for melanoma especially with the advent of targeted therapies. Gene expression studies examining primary melanomas have shown that increased expression of osteopontin (SPP1) is associated with poor prognosis. Studies subsequently reported higher blood levels in melanoma patients with metastatic disease than those without. This study was designed to determine whether osteopontin plasma concentrations in disease-free patients after initial treatment predict survival. An enzyme-linked immunosorbent assay (ELISA) was used to measure osteopontin levels in stored plasma samples (N=215) from participants in the Leeds Melanoma Cohort. AJCC stage at sampling was statistically significant associated with osteopontin levels (p=0.03). Participants with untreated stage IV disease at sampling (n=10) had higher median osteopontin levels compared to those with treated stage I-III disease (n=158) (p<0.001) confirming previous findings. There was a trend for increased risk of death with increasing osteopontin levels but this was not statistically significant. If a level of 103.14 ng/ml (95th centile of healthy controls) was taken as the upper end of the normal range then 2.5% of patients with treated stage I-III (4/110), 17.6% of patients with untreated stage III (3/17) and 30% of patients with untreated stage IV disease (3/10) had higher levels. These findings suggest that plasma osteopontin levels warrant investigation as a tumour marker in a larger study in which the significance of change in levels over time should be studied in relation to detectable disease recurrence.
Oncology Reports – Spandidos Publications
Published: Oct 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.